Blood-brain barrier disruption and complement activation in the brain following rapid correction of chronic hyponatremia.
In previous studies we developed a rat model in which demyelination is reproducibly produced following rapid correction of chronic hyponatremia and demonstrated that the development of demyelination in this model is strongly associated with NMR indices of blood-brain barrier (BBB) disruption. Because complement is toxic to oligodendrocytes, we evaluated the hypothesis that BBB disruption precipitated by correction of hypoosmolality is followed by an influx of complement into the brain, which then contributes to the demyelination that occurs under these conditions. We studied four groups of rats with immunocytochemical analysis using primary antibodies to IgG and the C3d split-fragment of activated complement: (1) normal rats; (2) rats in which hyponatremia was maintained for 7 days; (3) chronically hyponatremic rats in which the plasma [Na(+)] was rapidly corrected with hypertonic saline administration 20 h prior to perfusion; and (4) chronically hyponatremic rats in which the plasma [Na(+)] was rapidly corrected with hypertonic saline administration 5 days prior to perfusion. In normonatremic and uncorrected hyponatremic rats only background staining was observed in areas lacking a BBB and in blood vessel walls, whereas marked increases in IgG and C3d staining were seen in the brains of rats both 20 h and 5 days after rapid correction of hyponatremia. The staining intensity was significantly correlated with the degree of neurological impairment. These results provide evidence for functional BBB disruption following rapid correction of hyponatremia and support the hypothesis that complement activation may be involved in the pathogenesis of osmotic demyelination.
Baker
E A
EA
Division of Endocrinology and Metabolism, Georgetown University, Washington, DC, USA.
Tian
Y
Y
Adler
S
S
Verbalis
J G
JG
D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology*; D001923:Brain Chemistry / Q000276:immunology / Q000502:physiology; D003167:Complement Activation / Q000502:physiology*; D015933:Complement C3d / Q000032:analysis; D003711:Demyelinating Diseases / Q000503:physiopathology; D007010:Hyponatremia / Q000139:chemically induced / Q000503:physiopathology* / Q000628:therapy; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D009186:Myelin Sheath / Q000737:chemistry* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage; D015398:Signal Transduction / Q000502:physiology
D007074:Immunoglobulin G; D012462:Saline Solution, Hypertonic; D015933:Complement C3d